A Phase 1 interventional study of HH-006 and Placebo in Hepatitis B, sponsored by Huahui Health. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-07.
Sponsored by Huahui Health · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hepatitis B with a site in Australia — 6 open to participants now, 9 under way, none of them phase 3. Hepatitis B · Australia.
Among the 50 studies in Hepatitis B with a site in Australia, this one is the 39th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2022, is one of 12 in phase 1, and was the 41st registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →6 of the 50 studies in Hepatitis B with a site in Australia are open now. Recruiting first, the newest first:
bioLytical Laboratories · Sites in Australia
Ages 18+ · Healthy volunteers
AusperBio Therapeutics Inc. · Sites in Australia, China, Japan and 4 more countries
Ages 18–65
GigaGen, Inc. · Sites in Australia, United States, Hong Kong and 2 more countries
Ages 18+
Kirby Institute · Sites in Australia
Ages 18+ · Healthy volunteers
Kirby Institute · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 9 · Phase 4 4
First in 1999; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 103 across the 42 interventional studies, 186 across the 6 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 50 have an industry lead sponsor. The 10 most frequent:
Huahui Health is the lead sponsor of 18 studies on the registry; 5 are open to participants now.
Huahui Health has 1 study filed under Hepatitis B — fewer than ten, so there is no comparison to draw.
4 of the studies in Hepatitis B with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07569913bioLytical LaboratoriesA Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test | 2027-01-01 |
| NCT07059403Chimivac INCA Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults | 2027-04 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
| NCT06661148Epigenic Therapeutics, IncStudy of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies in Hepatitis B with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal antibody in healthy volunteers, and to determine its pharmacokinetic profile and immunogenicity.
This is a double-blind, placebo-controlled, Phase Ia study aimed to evaluate the safety and tolerability of HH-006 after single ascending doses given as subcutaneous injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HH-006
Drug: Placebo
Different dose levels of HH-006
Different dose levels of placebo
Number of participants with treatment emergent adverse events (TEAEs)
An AE that started on or after the first study treatment or that worsened after the first study treatment will be regarded as TEAEs.
Time frame: Day 1- Day 113
Severity of treatment emergent adverse events as measured by CTCAE v 5.0
Time frame: Day 1- Day 113
Duration of treatment emergent adverse events
Time frame: Day 1- Day 113
Cmax
Maximum observed HH-006 concentration
Time frame: Day 1-Day 113
Tmax
Time to maximum observed HH-006 concentration
Time frame: Day 1-Day 113
AUC0- last
Area under the plasma concentration-time curve from time zero to the last time point with measurable concentration
Time frame: Day 1-Day 113
AUC0-inf
AUC from time zero extrapolated to infinity
Time frame: Day 1- Day 113
t1/2
Apparent terminal half-life
Time frame: Day 1- Day 113
CL (SAD)
Apparent total body clearance
Time frame: Day 1-Day 113
CL/F (SAD)
Apparent clearance
Time frame: Day 1-Day 113
Vz/F (SAD)
Apparent terminal volume of distribution
Time frame: Day 1-Day 113
Titres of anti drug antibodies (ADA) to HH-006
To determine the immunogenicity of HH-006
Time frame: Day 1- Day 113
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Dec 2022, 7 months.
Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 7 months is below that.
Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HH-006